8-K: N2OFF, Inc. Enters $250,000 Loan Agreement with MitoCareX Bio Ltd., Issues Stock to Directors

N2OFF, Inc. has entered into a $250,000 loan agreement with MitoCareX Bio Ltd., guaranteed by L.I.A. Pure Capital Ltd., and issued 650,000 shares of common stock to its directors.

Summary

• N2OFF, Inc. has agreed to loan $250,000 to MitoCareX Bio Ltd., with the loan accruing interest at a rate based on the USD exchange rate fluctuation plus 3%.
• The loan term is six months, with both principal and accrued interest due at maturity.
• L.I.A. Pure Capital Ltd. has guaranteed the repayment of the loan by MitoCareX.
• If MitoCareX becomes a subsidiary of N2OFF, any outstanding loan amount will be deducted from future allocations to MitoCareX within the first year.
• N2OFF issued 650,000 shares of common stock to its directors as compensation for their board service, following stockholder approval at the annual meeting on November 13, 2024.

Sentiment

Score: 6

Explanation: The document outlines a standard loan agreement and stock issuance, which are neutral events. The potential for MitoCareX to become a subsidiary is a positive, but the short-term nature of the loan and variable interest rate introduce some uncertainty.

Positives

• The loan agreement provides MitoCareX with necessary funding for its immediate obligations and working capital.
• The loan is guaranteed by L.I.A. Pure Capital Ltd., reducing the risk for N2OFF.
• The stock issuance to directors aligns their interests with the company's success.
• The loan agreement includes a mechanism to recover the loan amount if MitoCareX becomes a subsidiary of N2OFF.

Negatives

• The loan is for a relatively short term of six months, requiring repayment in full at maturity.
• The interest rate is variable, based on the USD exchange rate fluctuation, which could increase the cost of the loan.
• The loan is dependent on the financial health of MitoCareX and the guarantor, L.I.A. Pure Capital Ltd.

Risks

• There is a risk that MitoCareX may not be able to repay the loan at maturity.
• The guarantor, L.I.A. Pure Capital Ltd., may not be able to fulfill its guarantee obligations.
• The variable interest rate could increase the cost of the loan for MitoCareX.
• The potential for MitoCareX to become a subsidiary of N2OFF introduces uncertainty regarding future financial arrangements.

Future Outlook

The loan agreement includes a provision that if MitoCareX becomes a subsidiary of N2OFF, the loan amount will be deducted from future allocations to MitoCareX within the first year, suggesting a potential future acquisition or closer relationship between the two companies.

Management Comments

• David Palach, CEO of N2OFF, signed the loan agreement on behalf of the company.
• Alon Silberman, Director of MitoCareX Bio Ltd., signed the loan agreement on behalf of the company.
• Kfir Silberman, CEO of L.I.A. Pure Capital Ltd., signed the loan agreement on behalf of the company.

Industry Context

This announcement reflects a common practice of companies providing loans to related entities or potential acquisition targets. The use of a guarantee from a third party is also a standard risk mitigation strategy. The stock issuance to directors is a typical form of compensation.

Comparison to Industry Standards

• The loan agreement is similar to other short-term financing arrangements in the biotech industry, where companies often seek bridge funding.
• The interest rate structure, tied to a fluctuating exchange rate plus a fixed percentage, is a common approach to managing currency risk.
• The issuance of stock to directors is a standard practice for compensating board members, aligning their interests with the company's performance.
• The guarantee from L.I.A. Pure Capital Ltd. is a typical risk mitigation measure seen in similar loan agreements.

Related Party Transactions

• The loan agreement between N2OFF and MitoCareX is a related party transaction, as is the guarantee by L.I.A. Pure Capital Ltd.

Stakeholder Impact

• Shareholders may view the loan as a potential investment opportunity if MitoCareX becomes a subsidiary.
• Directors benefit from the stock issuance as compensation for their service.
• MitoCareX benefits from the loan, providing necessary funding.
• L.I.A. Pure Capital Ltd. is exposed to the risk of guaranteeing the loan.

Next Steps

• MitoCareX is expected to use the loan for its immediate obligations and working capital.
• N2OFF will monitor the loan repayment and the potential for MitoCareX to become a subsidiary.
• N2OFF will continue to evaluate the performance of its directors.

Key Dates

Keywords

Loan Agreement, MitoCareX Bio Ltd, N2OFF, Inc., L.I.A. Pure Capital Ltd., Share Incentive Plan, Common Stock, Directors Compensation, Funding, Guaranty